Tatiana Prowell, Breast Cancer Scientific Lead at Office of Hematology & Oncology Products, US Food & Drug Administration, made the following post on Twitter:
“The first standardized definitions for efficacy endpoints in neoadjuvant breast cancer clinical trials (NeoSTEEP) are published in Journal of Clinical Oncology. Honored to have been a part of this working group. No paywall. Regulatory Drug development.”
For details click here.
Source: Tatiana Prowell/Twitter